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To examine whether serum levels of soluble interleukin-2 recep-
tor (sIL-2R) is a good marker of acute graft-versus-host disease
(aGVHD), they were measured in 37 patients receiving HLA-
haploidentical bone marrow transplantation (BMT). Grafts were
from HLA-haploidentical relatives. Conditioning regimen was
myeloablative including cyclophosphamide and toral body irradi-
ation. GVHD prophylaxis included tacrolimus (TAC)/solumedrol
(mPSL)/methotrexate (MTX) (n  11) and tacrolimus (TAC)/
solumedrol (mPSL)/methotrexate (MTX)/mycophenolate
mofetile (MMF) (n  27). Seventeen patients developed aGVHD
(Grade I, 9; Grade II, 5; Grade III, 3) after BMT. There was a
signiﬁcant correlation between occurrence of a GVHD and the
maximal serum level of sIL-2R. For 11 patients receiving GVHD
prophylaxis with TAC/mPSL/MTX, aGVHD occurred in 7 pa-
tients (63%). The mean maximal level of sIL-2R (SE) in 7
patients with a GVHD was 7086 (1066) and that in 4 patients
without aGVHD was 2770 (450). For patients with GVHD
prophylaxis with TAC/mPSL/MTX/MMF, aGVHD occurred in
10 patients (37%). The mean maximal level of sIL-2R in 10
patients with aGVHD was 3944 (655) and that in 17 patients
without aGVHD was 2566 (358). These data suggest that serum
levels of sIL-2R are useful for predicting the occurrence of
aGVHD after HLA-haploidentical BMT.
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EVALUATION FOR T CELL POPULATIONS AND CYTOKINE SHIFTS IN
NEWLY DIAGNOSED PEDIATRIC CHRONIC GRAFT-VERSUS-HOST DIS-
EASE
Schultz, K.R.1, Goldman, F.2, Aslanian, S.1, Shimizu, H.1, Krailo, M.3,
Wall, D.4, Gilman, A.L.5 1. BC Children’s Hospital/Univ. of British
Columbia, Vancouver, BC, Canada; 2. University of Iowa Medical
Center, Iowa City, IA; 3. Children’s Oncology Group, Arcadia, CA; 4.
Texas Transplant Institute, San Antonio, TX; 5. University of North
Carolina Chapel Hill, Chapel Hill, NC.
Little is known regarding the immunopathogenesis of chronic
graft-versus-host disease (cGvHD) in children. From 2001
through 2005, the Children’s Oncology Group (COG) performed
a randomized, double blinded, placebo controlled phase three
study for newly diagnosed extensive cGvHD in children and ado-
lescents, ASCT0031. Based on murine model data and limited
human studies, we hypothesized that cGvHD would be character-
ized by a Th1/Tc1 shift in T cell activation. Correlative immuno-
logic studies were performed on patients at time of enrollment to
evaluate for immune cell populations and T cell function, including
cytokine production. Twenty-seven control patients without evi-
dence of cGvHD had peripheral blood collected at 3, 6, 9, and 12
months post hematopoietic stem cell transplant (HSCT) and were
used as time matched controls. Fifty-four patients with newly
diagnosed extensive cGvHD were evaluated and divided as early
cGvHD (3–5 months post HSCT; N  20) or late-onset cGvHD
(6 months post HSCT; N 34). Signiﬁcance was determined by
either a 50% increase or decrease of the mean value compared to
control with a P value  .05. In the early-onset cGvHD patients,
the total number of CD3, CD4, and CD8T cell subsets were
all lower relative to non-cGVHD controls, although none were
signiﬁcantly different. In the late onset cGVHD patients, a non-
statistically signiﬁcant increase in CD4 and CD8 T cell pop-
ulations were noted compared to time-matched controls. Func-
tional evaluations for cytokine production after in vitro PMA/
Ionomycin stimulation (intra-cytoplasmic staining by FACS)
revealed no signiﬁcant difference in either Th1 cytokine produc-
tion (IFN) by CD4 or CD8 T cells with early-onset (P  .82,
0.81, respectively) or late onset cGVHD (P  .40, P  .33,
respectively). Evaluation for a Th2/Tc2 shift revealed that IL-4 in
either CD4 or CD8 T cells at early-onset cGvHD (P  .35,
0.11, respectively) or late-onset cGvHD (P  .54, P  .64, respec-
tively) was not different. Thus, we were unable to demonstrate
either a Th1/Tc1 or Th2/Tc2 shift associated with newly diag-
nosed cGvHD in children. These results may be different to
previous adult HSCT studies in that there may be a difference in
the biology of chronic GvHD in younger HSCT recipients or that
these studies were limited to evaluation at the time of presentation
of disease.
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BRONCHIOLITIS OBLITERANS AND BRONCHIOLITIS OBLITERANS OR-
GANIZING PNEUMONIA IN PEDIATRIC ALLOGENEIC STEM CELL
TRANSPLANT: AN INSTITUTIONAL EXPERIENCE
Duncan, C.N., Buonanno, M.R., Callaway, G.D., Lehmann, L.E.
Dana-Farber Cancer Institute, Boston, MA.
Bronchiolitis obliterans (BO) and bronchiolitis obliterans orga-
nizing pneumonia (BOOP) are rare, well-recognized complications
of allogeneic stem cell transplant (SCT). Both BO and BOOP are
associated with high morbidity and mortality in adult patients.
However, in the pediatric population, the incidence and morbidity
of these complications have not been well described. We report
our institutional experience of BO and BOOP in 449 pediatric
allogeneic SCT patients between January 1, 1993 and December
31, 2004. The source of stem cells in this population was as follows:
200 unrelated donors, 198 siblings, 42 parents, 5 extended family
members, and 4 half-siblings. A total of 18 patients (4%) developed
BO (n  11) or BOOP (n  7) during this time. The diagnosis of
BO was based on pulmonary function test (PFT) abnormalities
(decline in FEV1 20% of baseline or FEV1/FVC 70%) or
characteristic histologic changes on lung biopsy. BOOP was diag-
nosed by pathology only. The most common conditioning regimen
was cyclophosphamide (Cy) and total body irradiation (TBI), used
in 12 patients. Cytarabine/Cy/TBI was used in 3 cases, Busul-
fan/Cy in 2, and 1 patient received Etoposide/Cy. All but 2 patients
received bone marrow as a stem cell source; the remaining patients
received peripheral blood stem cells. Three of the patients received
stem cells from fully matched related donors; 6 of the donors were
related, but matched at less than 6 of the 6 typed HLA loci. Nine
patients received fully matched unrelated donor transplants. The
median time to diagnosis of BO or BOOP was 329 days from stem
cell infusion. Ten patients had abnormal computed tomography
scans at diagnosis. Six patients were diagnosed by PFTs alone, 9 by
pathology alone, and 3 by PFTs and pathology. All patients were
treated with immunosuppression: 16 patients received corticoste-
roids, 15 patients received calcineurin inhibitors, and 2 patients
received mycophenolate mofetil. Azithromycin was used in 3 pa-
tients for anti-inﬂammatory effects. Four patients were treated
with other medication regimens. One patient (6%) experienced
complete resolution of pulmonary disease. Three patients (17%)
achieved partial resolution. Four patients (22%) had progressive
disease. Ten patients (56%) died; 7 of pulmonary disease and 3 of
unrelated causes. BO and BOOP, while uncommon, are associated
with considerable morbidity and mortality in pediatric SCT, and
new therapeutic modalities are needed to improve the outcome of
these patients.
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CELLCEPT/CYCLOSPORINE AS PROPHYLAXIS AGAINST GRAFT- VER-
SUS-HOST DISEASE IN PEDIATRIC PATIENTS UNDERGOING ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Lakshminarayanan, S., Martin, P.L., Szabolcs, P., Driscoll, T.,
Parikh, S., Prasad, V., Kurtzberg, J. Duke University Medical Center,
Durham, NC.
Traditionally, pediatric patients are prophylaxed against acute
graft-versus-host disease (GvHD) with cyclosporine combined
with either methotrexate Mtx) or methylprednisolone (Pred). Mtx
worsens the severity of mucositis and renal insufﬁciency while pred
causes muscle wasting, hypertension and increased infections. Cell-
cept (myophenolic acid) is a better tolerated, less toxic agent with
synergistic immunosuppressive effects when combined with cyclo-
sporine or tacrolimus. We explored its use in combination with
cyclosporine in 21 pediatric patients undergoing allogeneic trans-
plantation. Patients with both malignant (n  7) and non-malig-
nant (n  14) conditions ranging in age from 2 weeks to 15 years
were transplanted after myeloablative preparative regimens with
either related bone marrow or cord blood (n 7) or unrelated cord
blood (n  14), using cellcept and cyclosporine for GVHD pro-
phylaxis. Cellcept and cyclosporine were administered intrave-
nously through the ﬁrst 40-60 days post transplant using cellcept at
a dose of 15mg/kg/dose IV q8H beginning on day -2 or -3. The
patient then transitioned to oral therapy at the same dose and
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schedule. There were no acute toxicities attributable to cellcept
observed in patients on IV therapy. All patients required treatment
with antihypertensive therapy(ies). Grossly infection rates did not
vary from those previously observed in conventionally treated
patients at our center. 18/21 patients engrafted neutrophils be-
tween day 9 and 52. Of the three patients who did not engraft, 2
died of infectious complications, one died of VOD and multi-
system organ failure. Of the 18 patients, evaluable for GvHD
follow-up ranged between 34 and 693 days (median 108 days), 6
patients had 0 grade I, 10 developed grade II, 1 grade III, and 1
grade 4 GVHD. Follow-up is too short to comment on the inci-
dence of chronic GvHD, but to date, 4 of 7 patients followed for
	100 days have developed chronic GvHD. While this data is early,
it appears that the incidence of both acute and chronic GvHD are
increased compared to previously reported series in patients
treated with cellcept instead of mtx (related bone marrow trans-
plantation) or pred (unrelated cord blood transplantation). En-
graftment in UCBT recipients was not compromised with the use
of IV cellcept administered in the peritransplant period. Additional
patients will need to be tested with this regimen and longer fol-
low-up is necessary to fully deﬁne the risks or beneﬁts of this
therapy.
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OUTCOMES ASSOCIATED WITH A STEROID-CONTAINING ACUTE GVHD
PROPHYLAXIS REGIMEN FOR MATCHED UNRELATED DONOR (MUD)
HEMATOPOIETIC STEM CELL TRANSPLANTATION
Hayes-Lattin, B., Leis, J.F., Curtin, P.T., Dunn, A., Epner, E.,
Fleming, W.H., Kovacsovics, T., Mauro, M.J., Moore, M., Simic, A.,
Subbiah, N., Maziarz, R.T. OHSU Cancer Institute, Center for He-
matologic Malignancies, Portland, OR.
Background: Previously reported randomized trials have
yielded differing conclusions about the addition of steroids to
GVHD prophylaxis for patients undergoing sibling allogeneic
transplant. Prophylaxis with cyclosporine plus methotrexate af-
ter MUD transplant has a reported grade 2–4 acute GVHD
incidence of 74%. MUD transplantation was initiated at OHSU
in 1996 using a 3-drug combination of cyclosporine, methotrex-
ate, and steroids in a single-arm prospective protocol to examine
the incidence and severity of GVHD and survival. Methods:
The analysis included all patients undergoing MUD transplant
who received GVHD prophylaxis with cyclosporine 2 mg/kg iv
BID from day 2, methotrexate 15 mg/m2 iv on day 1 and 10
mg/m2 iv on days 3 and 6, and methylprednisolone 0.25
mg/kg iv BID beginning on day 7 and tapering at day 28.
Patients were stratiﬁed by disease risk per CIBMTR classiﬁca-
tion. Patients with relapse and no GVHD were censored for
GVHD outcomes at therapeutic withdrawal of immunosuppres-
sion. Results: 124 patients received the 3-drug regimen, includ-
ing 50 with low-risk, 43 with intermediate-risk, and 31 with
high-risk disease. One hundred sixteen (94%) of the MUD
grafts were matched at 6 out of 6 HLA-antigens. Eight patients
were not evaluable for GVHD due to death prior to engraft-
ment. The maximum grade of acute GVHD is shown in Table
1. Sixty-four (55%) had grade 0–1 acute GVHD. Fifty-two
(45%) developed grade 2–4 acute GVHD at a median onset of
day 29. Twenty-eight (24%) developed grade 3–4 acute
GVHD. Patients with low-risk disease had a median survival of
29 months and a 5-year OS of 42%, whereas those with inter-
mediate/high-risk had a median survival of 10 months and a
5-year OS of 23%. The rate of disease relapse was 15% for both
the low and intermediate/high-risk groups. Preliminary infec-
tion analysis among 64 patients demonstrated an incidence of all
infections greater than 70%. Conclusions: The observed rate
of grade 3–4 acute GVHD using a 3-drug prophylaxis strategy
that includes steroids after MUD transplantation was low and
delayed in onset when compared to previous trials of 2-drug
combinations. The rate of disease relapse was low and the
overall survival was comparable to other published strategies.
Preliminary analysis suggests a high rate of infections. Addi-
tional analyses are planned to explore rates of chronic GVHD,
as well as other potential steroid-related events such as hyper-
glycemia, musculoskeletal complications, alveolar hemorrhage
or thrombotic microangiopathy (Table).
Maximum Acute GVHD Grade
Number Percent
Grade 0 40 34%
Grade 1 24 21%
Grade 2 24 21%
Grade 3 15 13%
Grade 4 13 11%
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FAILURE OF MEMORY T CELLS TO INDUCE GVHD IS A RESULT OF AN
ABORTIVE ALLORESPONSE
Chen, B.J., DeOliveria, D., Cui, X., Chao, N.J. Duke University
Medical Center, Durham, NC.
We and others previously reported that effector memory T cells
(TEM) can not cause graft-versus-host disease (GVHD). In the
current study, we further investigated the potential of this ap-
proach, the role of central memory T cells (TCM) in GVHD, and
the underlying mechanisms. The study was mainly performed in a
major histocompatibility complex mismatched model (unprimed
C57BL/6 [H2b] to BALB/c [H2d]). Naive T cells
(CD62LCD45RBCD44low), memory T cells (all other T cells
except naive T cells), TCM (both CD62LCD45RB and
CD62LCD45RBCD44high), and TEM (CD62L) were obtained
by cell sorting. An in vivo T cell titration experiment demonstrated
memory T cells are at least 3-log less potent in mediating GVHD
as compared with bulk T cells because infusion of as many as 1 
106 total memory T cells failed to induce GVHD while infusion of
as few as 1  103 bulk T cells was able to induce GVHD in this
model. Because failure of TEM to induce GVHD may be related to
their inability to home to secondary lymphoid organs, we next
asked whether TCM, which have the ability to home to second-
ary lymphoid organs, are able to induce GVHD. The results
indicated that neither TCM nor TEM was able to induce GVHD
even when as many as 1  106 cells were given (Table). All TCM
and TEM recipients survived more than 60 days. In contrast, all
naive T cell recipients died of GVHD within 40 days after
transplantation. These data directly demonstrate that similar to
TEM, TCM can not induce GVHD, suggesting that there are
other mechanisms involved in the inability of memory T cells to
induce GVHD. To further understand these mechanisms, we
then studied memory T cells’ responses to alloantigens in vitro.
As expected, memory T cells failed to elicit cytotoxicity and
proliferated poorly against alloantigens in standard 5-day mixed
lymphocyte culture as compared with both bulk and naive T
cells. However, the proliferation response of memory T cells
were much more comparable with those of bulk and naive T
cells when the culture time was shortened. More strikingly, the
frequencies of IL-2 secreting cells measured by 42-hour ELIS-
POT assay were similar between naive and memory T cells.
These data indicate that memory T cells from unprimed animals
are able to respond to alloantigens initially, but fail to develop
into full potential. The “abortive” immune response, which may
be a feature of non-allospeciﬁc memory T cells in response to
alloantigens, explains why memory T cells can not induce
GVHD (Table).
Central Memory T Cells Cannot Cause GVHD
Groups % Original body weight 60-Day survival
day 21 day 56 -
TCD BM alone 96.4% 95.8% 100%
Naive 70.2% N/A (all dead) 0%
Effector memory 94.2% 93.9% 100%
Central memory 95.6% 98.05 100%
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